No, Trileptal is NOT an antipsychotic
Trileptal (oxcarbazepine) is an antiepileptic drug (AED), not an antipsychotic medication. It is FDA-approved specifically for the treatment of partial-onset seizures in adults and children 1.
Drug Classification and FDA-Approved Indications
According to the FDA drug label, Trileptal is classified as an antiepileptic drug (AED) with the following approved uses 1:
- Monotherapy or adjunctive therapy for partial-onset seizures in adults
- Monotherapy for partial-onset seizures in children ≥4 years of age
- Adjunctive therapy for partial-onset seizures in children ≥2 years of age
The American Academy of Neurology and American Epilepsy Society guidelines confirm oxcarbazepine's role as an antiepileptic medication, finding it appropriate for adjunctive treatment of refractory partial seizures in both adults and children 2.
Off-Label Psychiatric Use Does Not Change Its Classification
While some research suggests oxcarbazepine has been used off-label for psychiatric conditions (including mood stabilization, bipolar disorder, and behavioral symptoms in children) 3, 4, this does not make it an antipsychotic. The evidence describes it as having "possible" utility in psychiatric symptoms, but these are non-FDA-approved indications 3.
Key Distinction:
- Antipsychotics are medications designed to treat psychosis, schizophrenia, and related disorders
- Antiepileptics like Trileptal work primarily through voltage-gated sodium channel blockade to prevent seizures
- Off-label psychiatric use of an antiepileptic does not reclassify the medication
Important Clinical Caveat
One research study incorrectly refers to carbamazepine and oxcarbazepine as "antipsychotic drugs" 5, but this is a clear error in terminology. The FDA label, official guidelines, and the vast majority of medical literature consistently classify oxcarbazepine as an antiepileptic drug 2, 1.